Blood-Based Biomarkers for Alzheimer’s Disease: What Neurologists Need to Know
Date: October 18, 2026
Time: 3:30 pm to 5:00 pm
Room: Silver Pearl Ballroom 1
Track: Satellite Symposia
Session Description
Blood-based biomarkers are transforming the diagnosis and management of Alzheimer’s disease by offering a non-invasive, accessible, and cost-effective alternative to traditional diagnostic methods. This session will highlight the latest advancements in blood test research, pairing it with real-world experience from clinicians now using these tests in their own practices. Faculty will explore what is working well in the clinic, the key challenges to broader adoption, including accessibility, integration into clinical workflows, and clinician and patient education. Attendees will gain practical insights into applying blood-based biomarkers in clinical settings, including their role in diagnosing cognitive impairment, guiding treatment decisions, and improving ongoing patient care and management.
The American Neurological Association (ANA) does not endorse the product(s) and/or service(s) advertised or for the company that advertises, manufactures, distributes, or promotes the products and services.
This session is not sponsored or programmed by the American Neurological Association. These speakers are presenting on behalf of and are paid consultants for Global CEOInitiative. There aren’t continuing education credits for this session.



